We next investigated the involvement of CCR5 in the pathology of a T-cell-driven colon inflammation using a TNBS-induced model of colitis in both wild-type mice and CCR5−/− animals that received either placebo or maraviroc treatment (50 mg/kg for 5 days, starting one day after colitis induction) (Fig. 2A–C). This evidence concerns the gene CCR5 and colitis.